Filing Flows › Iovance Biotherapeutics (IOVA) › Q3 2026 › vs Q2 2026
Iovance Biotherapeutics (IOVA) Q3 2026 vs Q2 2026 (quarter over quarter)
Iovance Biotherapeutics's revenue rose $22.2M (+22%) from $99.3M in Q2 2026 to $121M in Q3 2026.
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $121M | $99.3M | $22.2M | +22% |
| Other income, net | $2.3M | $3.2M | −$906K | -28% |
| Net loss | $22.3M | $47.3M | −$25.0M | -53% |
| Costs & expenses | $146M | $151M | −$5.2M | -3% |
| Operating costs | $145M | $151M | −$5.8M | -4% |
| Income tax | $614K | −$1.4M | $2.0M | — |
| Cost of revenue | $48.0M | $43.6M | $4.4M | +10% |
| Research & development | $49.3M | $58.9M | −$9.5M | -16% |
| General & admin | $38.6M | $39.3M | −$697K | -2% |
| Other operating costs | $9.5M | $9.5M | −$3K | 0% |
| Operating cash sources | $22.3M | $47.3M | −$25.0M | -53% |
| Depreciation & amortization | $3.8M | $3.8M | $13K | +0.3% |
| Share-based compensation | $11.8M | $11.7M | $100K | +0.9% |
| Working capital & other | $2.2M | −$29.0M | $31.2M | — |
| Cash used in operations | $4.5M | $60.8M | −$56.4M | -93% |
| Net loss absorbed | $22.3M | $47.3M | −$25.0M | -53% |
Questions
How much did Iovance Biotherapeutics's revenue grow quarter over quarter in Q3 2026?
Iovance Biotherapeutics's revenue rose $22.2M (+22%) from $99.3M in Q2 2026 to $121M in Q3 2026.